你即將離開本站

並前往https://www.nejm.org/doi/full/10.1056/NEJMoa1913662

Overall Survival with Osimertinib in Untreated, EGFR-Mutated ...

A phase 3 trial compared first-line osimertinib with other EGFR-TKIs in patients with EGFR mutation–positive advanced non–small-cell lung ...

確定！ 回上一頁

查詢 「advanced stage醫學中文」的人也找了：

  1. Advanced
    2.